Table 1 Demographic and pre-treatment data according to the treatments employed
Type of treatment | Posterior stabilization with decompression (n = 18) | Posterior stabilization without decompression (n = 15) | Radiotherapy (n = 55) |
|---|---|---|---|
Male vs. female | 12:6 | 9:6 | 40:15 |
Age (years), mean | 39–83, 62.5 ± 11.8 | 40–82, 63.1 ± 13.9 | 36–85, 65.5 ± 11.5 |
The level of the spine that exhibited the greatest tumor-related spinal cord compression | |||
 C1-T2 level | 5 | 3 | 9 |
 T3-L1 level | 6 | 4 | 22 |
 L2-S1 level | 7 | 8 | 24 |
No. of affected vertebral body, mean | 1–4, 2.1 ± 1.1 | 1–12, 3.5 ± 3.4 | 1–9, 3.3 ± 2.2 |
Primary site | |||
 Lung | 6 | 5 | 31 |
 Kidney | 3 | 1 | 2 |
 Prostate | 1 | 1 | 4 |
 Liver | 3 | 3 | 6 |
 Breast | 1 | 3 | 0 |
 Others | 4 | 2 | 12 |
No. of VAS 0 | 0 (0%) | 0 (0%) | 6 (10.9%) |
Transverse location | |||
 A | 3 | 5 | 23 |
 AP | 2 | 2 | 15 |
 AF | 9 | 6 | 6 |
 APF | 4 | 2 | 11 |
ESCC scale | |||
 1b | 9 | 7 | 28 |
 1c | 5 | 5 | 19 |
 2 | 2 | 3 | 7 |
 3 | 2 | 0 | 1 |
Spinal instability neoplastic score | 10.1 ± 2.4 | 10.5 ± 2.5 | 9.3 ± 2.4 |
Additional adjuvant therapy | Radiotherapy 8, chemotherapy 11, BMA 3, no 2 | Radiotherapy 11, chemotherapy 9, BMA 2, no. 1 | Chemotherapy 20, BMA 17, no. 17 |
Survival period (months), mean | 1–116, 16.0 ± 28.0 | 2–14, 7.2 ± 3.9 | 0.3–34, 7.7 ± 7.5 |
Pre-treatment Barthel index, mean | 49–100, 81.5 ± 20.7 | 70–85, 77.5 ± 10.6 | 10–100, 68.0 ± 30.6 |